Cargando…

The metabolic and mitogenic properties of basal insulin analogues

CONTEXT: Retrospective, observational studies have reported an association between diabetes treatment with insulin and a higher incidence of cancer. OBJECTIVE: Overview the literature for in vitro and in vivo studies of the metabolic and mitogenic properties of basal insulin analogues and assess the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tennagels, Norbert, Werner, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581051/ https://www.ncbi.nlm.nih.gov/pubmed/23373726 http://dx.doi.org/10.3109/13813455.2012.754474

Ejemplares similares

Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue
por: Werner, Ulrich, et al.
Publicado: (2014)

Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
por: Tennagels, N., et al.
Publicado: (2013)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats
por: Tennagels, N., et al.
Publicado: (2013)

Systematic Evaluation of the Metabolic to Mitogenic Potency Ratio for B10-Substituted Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2012)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2
por: Pierre-Eugene, Cécile, et al.
Publicado: (2012)

Minimizing Mitogenic Potency of Insulin Analogues Through Modification of a Disulfide Bond
por: Ong, Shee Chee, et al.
Publicado: (2022)

A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues
por: Baricevic, Ivona, et al.
Publicado: (2015)

Insulin Receptor Phosphorylation by Endogenous Insulin or the Insulin Analog AspB10 Promotes Mammary Tumor Growth Independent of the IGF-I Receptor
por: Gallagher, Emily Jane, et al.
Publicado: (2013)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia
por: Buturovic, Belma Ascic, et al.
Publicado: (2014)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
por: Choe, Eun Yeong, et al.
Publicado: (2012)

Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
por: Kalra, Sanjay
Publicado: (2015)

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells
por: ter Braak, Bas, et al.
Publicado: (2015)

Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice
por: Ardaiz, Nuria, et al.
Publicado: (2021)

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
por: Svensson, Ann-Marie, et al.
Publicado: (2020)

Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study
por: Bjekić-Macut, Jelica, et al.
Publicado: (2018)

Safety and Efficacy of Modern Insulin Analogues
por: Yoo, Hye Jin, et al.
Publicado: (2013)

Cardioprotective role of insulin: Advantage analogues
por: Maiti, Rituparna, et al.
Publicado: (2012)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel
por: Chawla, Manoj, et al.
Publicado: (2020)

Insulin Sensitivity, Inflammation, and Basal Metabolic Rate in Adults with Sickle Cell Anemia
por: Akinlade, Kehinde Sola, et al.
Publicado: (2018)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
por: Barnett, A H
Publicado: (2012)

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Review of Insulin and its Analogues in Diabetes Mellitus
por: Mane, Krishnappa, et al.
Publicado: (2012)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2011)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
por: Sheng, Xiaoli, et al.
Publicado: (2019)

On ceramides, other sphingolipids and impaired glucose homeostasis()
por: Larsen, Philip J., et al.
Publicado: (2014)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

Facile folding of insulin variants bearing a prosthetic C-peptide prepared by α-ketoacid-hydroxylamine (KAHA) ligation
por: Boross, Gábor N., et al.
Publicado: (2018)

A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the ACHIEVE Control study
por: Meneghini, Luigi F., et al.
Publicado: (2020)

Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells
por: Weinstein, Doron, et al.
Publicado: (2014)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k27p8c9ipnod2oog3fjm40jaub